H.E.L signs distribution agreement with Particular Sciences | H.E.L Group

H.E.L signs distribution agreement with Particular Sciences

Particular Sciences to distribute H.E.L’s product portfolio in Eire and Northern Ireland.

 

London, UK, 22nd July 2021: H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today announced a distribution agreement with Particular Sciences Ltd, Dublin. Under this agreement, Particular Sciences become the exclusive distributor of H.E.L’s products in Eire (Ireland) and Northern Ireland, effective from 1st June 2021.

Particular Sciences started in 1989, supplying laser particle sizing solutions to the Irish market and has since grown to represent twenty leading instrument companies across a wide range of scientific applications. The distributor supports systems at approximately 250 companies across Eire and Northern Ireland, with head offices in Dublin, supplemented by team members working remotely and at customer sites. Customers in Eire and Northern Ireland can now contact Particular Sciences directly with any inquiries for H.E.L Group products.

H.E.L is supplementing the growth of their direct sales team around the globe with strategic distribution arrangements. As well as addressing new, or growing, geographies, recent world events have highlighted the benefits of having in-region representation. This announcement follows the recent appointment of Brice Oh as Asia-Pacific Sales Director and highlights the importance of distributor relationships around the world.

Paul Orange, Chief Commercial Officer of H.E.L Group, commented: “We look forward to working with the Particular Sciences team to help customers in Ireland fulfill their potential – they have a fantastic reputation in supporting their customers, and we see a great opportunity for H.E.L to grow in this market. Ireland has a world-class scientific environment featuring academic research, local businesses, and global enterprises – especially in the pharma and bio-pharma industries. Our H.E.L portfolio is a natural fit with this customer base, and we are delighted to offer it through Particular Sciences.”

Click here to download PRESS RELEASE


For further information please contact:

Zyme Communications
Sarah Jeffery
Tel: +44 (0)7771 730919
E-mail: sarah.jeffery@zymecommunications.com